bumetanide NDC 72603-299

NDC codes

FDA NDC Directory

Product NDC (as listed)72603-299Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72603-0299Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72603-299-01	72603029901	100 TABLET in 1 BOTTLE (72603-299-01)Marketed from Sep 1, 2025
72603-299-02	72603029902	500 TABLET in 1 BOTTLE (72603-299-02)Marketed from Sep 1, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): bumetanide
Generic name (nonproprietary): bumetanide
Active ingredients: Bumetanide — 2 mg/1
Dosage form: Tablet
Route: Oral
Labeler: NorthStar Rx, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 074225
Marketing start: Sep 1, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Increased Diuresis at Loop of Henle (Physiologic effect)
Identifiers: Product ID 72603-299_3aa9066b-354b-4f6b-87b9-2752a3a51f6bSPL ID 3aa9066b-354b-4f6b-87b9-2752a3a51f6bSPL set ID 6b92460e-48ba-44bb-9b61-5e65e5fd82cdRxCUI 197417, 197418, 197419UNII 0Y2S3XUQ5HUPC 0372603298017, 0372603297010, 0372603299014
Pharmacologic class: Loop Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472603029901 followed by a unit qualifier and the quantity

Package 72603-0299-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 7, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Bumetanide tablets are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 074225

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 074225
Product	Strength	Form · route	Labeler	Product NDC
bumetanide	Bumetanide .5 mg/1	TabletOral	NorthStar Rx, LLC	72603-297
bumetanide	Bumetanide 1 mg/1	TabletOral	NorthStar Rx, LLC	72603-298
bumetanide	Bumetanide 2 mg/1	TabletOral	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-902
bumetanide	Bumetanide .5 mg/1	TabletOral	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-900
bumetanide	Bumetanide 1 mg/1	TabletOral	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-901